ASCO news from FierceBiotech
NewsSPOTLIGHT: Avastin leaves ASCO ahead of Erbitux
Shares of Genentech have been buoyed by news from ASCO that Avastin will likely be preferred to Erbitux for treating lung cancer. Avastin offers an extra month of average survival time compared to Read more...
ALSO NOTED: Acorda shares soar; Lexicon wins fast track; NIH grants $533N in research funds; and much more...
> News yesterday that Acorda Therapeutics' experimental MS drug helped patients walk better sent its shares up 27 percent. Read more...
ALSO NOTED: ASCO already churning out news; Lilly, FDA ironing out Zyprexa shot problems; and much more...
> Today marks the start of the annual ASCO. Here's a round-up of some of the news coming out of the conference. Read more...
SPOTLIGHT: Novartis touts cancer data
Novartis has released positive data for RAD001 in advance of ASCO. According to interim data the therapy extended time without tumor growth from 1.9 months to 4 months and reduced the risk of Read more...
ASCO braces for massive data dump before meeting
The analysts devoted to tracking biotech companies in the oncology arena will have their hands full tomorrow night at 9 p.m. EST. That's when ASCO will do an online data dump in advance of its annual Read more...
Onyx CEO to retire
Hollings C. Renton, CEO of Onyx Pharmaceuticals, announced plans to retire next year. He will remain chairman of the board of directors. The company has initiated a search for his successor. Onyx Read more...
SPOTLIGHT: Hollis-Eden skyrockets on preclinical cancer data
At the 2007 ASCO Breast Cancer Symposium, Hollis-Eden reported impressive data for HE3235, a preclinical candidate for breast cancer. HE3235 significantly inhibited the incidence of new tumors and Read more...
| Press ReleasesPRESS RELEASE: Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium Preclinical Data Show Lasting Anti-Tumor Effect of Novel Drug Candidate SAN DIEGO -- Hollis-Eden Pharmaceuticals, Read more... |
Get more ASCO coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets